182

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Capsules/Tablets

Part A (all doses)

Prescriber Criteria: Consultant Endocrinology & Diabetes
Specialist Family Medicine [Renewals only]

Outpatient and Inpatient use:

1. Diabetes Mellitus Type 2

Reserved for patients with HbA1c >7% and <10% * despite treatment with metformin, or sulfonylurea who have either:

- Established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease (defined as diabetes with microalbuminuria or macroalbuminuria of lower eGR [<60mL/min/1.73m^2] or both]
  Or
- BMI >30kg/m^2 who need to lose weight, or weight gain minimisation.

* HbA1c blood test **MUST** be attached with the application for the request to be processed.

Duration of Approval:
3 years

Part B (10mg only)

Prescriber Criteria: Consultant Cardiologist
Consultant Cardiothoracic Surgeon
Resident Specialist Cardiology
Resident Specialist Cardiothoracic Surgery

Outpatient and Inpatient use:

1. Chronic Heart Failure

Reserved for the treatment of patients with symptomatic chronic heart failure.

Duration of Approval:
3 years

Part C (10mg only)

Prescriber Criteria: Consultant Nephrologist
Resident Specialist Nephrology

Outpatient and Inpatient use:

1. Chronic Kidney Disease

Reserved for patients with chronic kidney disease (eGFR ≥ 20mls/min/1.73m^2) and any one of the below:

- Urine albumin: creatinine ratio >200mg/g
- Symptomatic heart failure irrespective of ejection fraction
- Cardiovascular disease
- Type 2 diabetes irrespective of HbA1c and urine albumin: creatinine ratio.

Duration of Approval:
3 years